Xoma files expanded complaint against Biosite
This article was originally published in Clinica
Executive Summary
Xoma has filed an amended and supplemental complaint as part of its ongoing litigation against Biosite. Earlier this year, Biosite began using a new antibody expression technology, which it claimed allowed it to avoid using patents licensed from Xoma (see Clinica No 997, p 19).